Doximity (DOCS) is likely bracing for a wider range of outcomes in 2025 amid strong near-term conditions, Morgan Stanley said in a Thursday note.
"Near term conditions are robust and should be supportive to guiding in line with the Street estimate," the report said.
Still, macro risks have intensified, with pharma companies contending with uncertainty around tariffs and disruptions at the US Food and Drug Administration, the note added.
"As such, line of sight into the back half of the year is clouded," the report said.
Morgan Stanley cut its price target to $60 from $71 while keeping its equalweight rating to reflect multiple contraction.
Price: 55.07, Change: +0.85, Percent Change: +1.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。